M&A

M&A

Strides Pharma to acquire US pharma co Endo's facility, ANDAs for $24-M

Press Release  

Bengaluru-based, publicly-listed Strides Pharma Science Ltd, through its wholly owned subsidiaries, has entered into agreements with subsidiaries of Dublin, Ireland headquartered Endo International plc to acquire the latter's manufacturing facility at Chestnut Ridge, NY (USA), and a basket of ANDAs (abbreviated new drug applications), for USD 24 million. The deal is aimed to bolster Strides' US presence through the acquisition of a multi dosage facility in the US and a basket of ANDAs cutting across multiple therapeutic segments. The facility at Chestnut Ridge has an annual capacity of 2 billion units across semisolids, liquids, nasal sprays along with oral solids.